
Conference Coverage
about 1 month ago
EURETINA 2026: Why peripheral vision matters in macular degenerationabout 1 month ago
EURETINA 2026: Real-world evidence on retinal biosimilarsTrending on the Eye Care Network
Q&A: What the FDA’s class-wide NAION warning on GLP-1s means for eye care
How Lambert-Eaton myasthenic syndrome presents around the eyes
Dazodalibep data put Sjögren screening in focus for ophthalmologists
The interplay between cardiac disease and the eye
Longer anti-VEGF intervals in AMD, BRVO, and DME: 3 clinical cases
Latest News

The interplay between cardiac disease and the eye

What every cataract surgeon should know about vitreoretinal examinations

Oral rhodopsin correction in adRP: Ester Carreño, MD, PhD, weighs in

Stool biomarker uncovers silent bowel disease in uveitis patients

Retinal imaging as a window into atrial fibrillation

Shorts










Digital Edition








Podcasts
Continuing Medical Education
All News

A vascular link: erectile dysfunction may signal glaucoma risk in men
An association has been identified between primary open-angle glaucoma and erectile dysfunction.

Omur Ucakhan, MD, explains why artificial tears are not interchangeable and how dry eye phenotype should guide formulation choice.

CHMP backs Accord Healthcare’s Lucentis biosimilar Fovlussea for nAMD, DMO, RVO and CNV ahead of an EC decision.

A higher risk of central serous chorioretinopathy and serous pigment epithelial detachment are associated with varicose veins.

AVT29, filed as a line extension to Mynzepli, reaches EMA before its phase 3 comparative trial in DME reads out in mid-2027.

Real-world VOYAGER data at EURETINA 2026 show vision and anatomic outcomes with faricimab across nAMD, DME, and RVO.

At EURETINA 2026, Roger Goldberg, MD, MBA, explains why EYP-1901 missed LUGANO's primary endpoint despite matched anatomy, clean safety and a 42% cut in treatment burden.

Ashish Sharma, MD, on what real-world data show about switching and long-term outcomes with retinal biosimilars.

Serena Salvatore, MD, discusses the retinal laser training gap, persistent laser myths, simulation and practical advice for safer laser at EURETINA 2026.

Ester Carreño, MD, PhD, explains how to tell retinitis pigmentosa from uveitis and why genetic confirmation now matters more.

Women’s systemic and ocular health associated with pregnancy is a focus at EURETINA 2026 in Vienna.

Three EURETINA 2026 e-posters examine OCT/OCTA biomarkers and real-world switching to faricimab or aflibercept 8 mg in nAMD.

Three studies use OCT and OCTA to track AMD treatment response, flag diabetic retinopathy before oedema and confirm ocular toxoplasmosis.

Inherited metabolic diseases affect the retina even before the systemic diagnosis is established.

An industry symposium on intravitreal 4D-150 and a course on subretinal delivery lead gene therapy content at EURETINA 2026, alongside IRD courses and trial readouts.






















